The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
 
Dai Maruyama
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Genmab; Janssen; Kyowa Kirin; MSD; Mundipharma; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Sanofi; SymBio Pharmaceuticals; Takeda; Zenyaku Kogyo
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Genmab; Janssen; Pfizer; Roche; Sanofi
Research Funding - Abbvie; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Genmab; Janssen; Kyowa Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Roche; Sanofi; SymBio Pharmaceuticals; Taiho Pharmaceutical; Takeda; Zenyaku Kogyo
 
Erica Gomez
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Muhammad Jalaluddin
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
 
Kamel Izeradjene
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Edward Greenberg
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Cyril Ramathal
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Matthew Ku
Consulting or Advisory Role - AbbVie; Roche